Radiant Research/CRA Enrolls More Than 8,000 Subjects
Radiant Research/CRA has completed enrollment for the Dynavax Technologies Phase III clinical trial
Radiant Research/Clinical Research Advantage (Radiant/CRA), a wholly owned clinical trial site management organization, has completed enrollment for the Dynavax Technologies Phase III clinical trial of HEPLISAV-B™, an investigational adult hepatitis B vaccine. Radiant/CRA was awarded 100 percent of the study and 40 of its sites are conducting the trial, which has randomized over 8,250 adults, including over 1,100 diabetic subjects. The sites completed the enrollment three months ahead of schedule without the use of an outside recruiting company.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
